(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 27.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Autolus Therapeutics's revenue in 2026 is $137,434,000.On average, 11 Wall Street analysts forecast AUTL's revenue for 2026 to be $40,912,538,091, with the lowest AUTL revenue forecast at $38,198,530,129, and the highest AUTL revenue forecast at $43,040,597,328. On average, 11 Wall Street analysts forecast AUTL's revenue for 2027 to be $53,923,263,212, with the lowest AUTL revenue forecast at $41,631,656,982, and the highest AUTL revenue forecast at $62,448,817,175.
In 2028, AUTL is forecast to generate $78,040,380,093 in revenue, with the lowest revenue forecast at $46,521,665,441 and the highest revenue forecast at $114,379,854,719.